Chromocell Therapeutics Corp.
CHRO
Get informed when a big investor buys or sells
+ FollowMarket Cap$88.66M
Close$
$-0.30
122.2% downside
Current Fair Value
122.2% downsideOvervalued by 122.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $88.66 Million |
|---|---|
| Enterprise Value | $111.07 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-23.04 |
| Beta | 3.29 |
| Outstanding Shares | 3,539,464 |
Return
| Return on Equity | 4767.29% |
|---|---|
| Return on Assets | -52.10% |
| Return on Invested Capital | -28.62% |
Valuation & Multiples
| P/E Ratio | -0.05 |
|---|---|
| PEG | -0.01 |
| Price to Sales | 0.11 |
| Price to Book Ratio | -1.35 |
| Enterprise Value to Revenue | 2.56 |
| Enterprise Value to EBIT | -3.68 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.42 |
| Debt to Equity | -31.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
March 19, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Pelthos Therapeutics Inc.
92 employees
CEO: Scott Plesha Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medic...